Drug intelligence / Profile preview

SCT650

Development stage: Unknown
Lead developer: Sinocelltech
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

SCT650 is an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy developed by Sinocelltech for the treatment of B-cell hematologic malignancies. The therapy involves the ex vivo genetic modification of a patient's own T cells to express a chimeric antigen receptor (CAR) that specifically targets the CD19 antigen, a protein widely expressed on the surface of B-cell lineage cells. Once these engineered T cells are expanded and re-infused into the patient, they recognize and eliminate CD19-positive malignant cells through T-cell mediated cytotoxicity. SCT650 is currently being evaluated in early-stage clinical trials for various B-cell lymphomas and leukemias.

Other names: CAR-T单抗

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on SCT650.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCT650.

Explore the full profile